Abeona Therapeutics Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2018

Antidilutive securities excluded from computation of earnings per share

We did not include the following potentially dilutive securities in the computation of diluted net loss per common share because the securities were anti-dilutive during the periods presented:

	For the years ended December 31,
	2018		2017		2016
Warrants		1,820,686		2,934,685		3,736,617
Stock options		5,841,805		5,429,727		4,771,560
Total		7,662,491		8,364,412		8,508,177

Employee Stock Option [Member]

Stock-based compensation allocation

The following table summarizes stock-based option compensation for 2018, 2017 and 2016, which was allocated as follows:

	For the years ended December 31,
	2018		2017		2016
Research and development	$	3,913,000	$	1,668,000	$	1,219,000
General and administrative		4,265,000		2,976,000		3,610,000
Stock-based compensation expense included in operating expense		8,178,000		4,644,000		4,829,000
Total stock-based compensation expense		8,178,000		4,644,000		4,829,000
Tax benefit		—		—		—
Stock-based compensation expense, net of tax	$	8,178,000	$	4,644,000	$	4,829,000

Restricted Stock [Member]

Stock-based compensation allocation

The following table summarizes restricted stock-based compensation for 2018, 2017 and 2016, which was allocated as follows:

	For the years ended December 31,
	2018		2017		2016
Research and development	$	—	$	—	$	200,000
General and administrative		688,000		1,272,000		3,232,000
Stock-based compensation expense included in operating expense		688,000		1,272,000		3,432,000
Total stock-based compensation expense		688,000		1,272,000		3,432,000
Tax benefit		—		—		—
Stock-based compensation expense, net of tax	$	688,000	$	1,272,000	$	3,432,000